TY - JOUR
T1 - Standardized Outcomes in Nephrology—Glomerular Disease (SONG-GD)
T2 - establishing a core outcome set for trials in patients with glomerular disease
AU - Carter, Simon A.
AU - Lightstone, Liz
AU - Cattran, Daniel
AU - Bagga, Arvind
AU - Barbour, Sean J.
AU - Barratt, Jonathan
AU - Boletis, John
AU - Caster, Dawn
AU - Coppo, Rosanna
AU - Fervenza, Fernando C.
AU - Floege, Jürgen
AU - Hladunewich, Michelle
AU - Hogan, Jonathan J.
AU - Kitching, A. Richard
AU - Lafayette, Richard
AU - Malvar, Ana
AU - Radhakrishnan, Jai
AU - Rovin, Brad H.
AU - Zhang, Hong
AU - Gutman, Talia
AU - Howell, Martin
AU - Logeman, Charlotte
AU - Shen, Jenny I.
AU - Teixeira-Pinto, Armando
AU - Alexander, Stephen I.
AU - Cho, Yeoungjee
AU - Craig, Jonathan C.
AU - Harris, David
AU - Johnson, David W.
AU - Kerr, Peter G.
AU - Ryan, Jessica
AU - Viecelli, Andrea K.
AU - Wang, Angela Yee Moon
AU - Wilkie, Martin
AU - Scholes-Robertson, Nicole
AU - Tong, Allison
AU - SONG-GD Initiative
PY - 2019/6
Y1 - 2019/6
N2 - Glomerular diseases (GDs) impose a substantial burden on patients and health systems, and they are a major cause of end-stage kidney disease (ESKD) worldwide.1 The causes and clinical features of GD are diverse, yet as a group they share many symptoms, treatments, and outcomes (Table 1). Patients with primary and secondary GDs have mortality rates 2.7- and 3.9-fold higher than the general population, respectively, higher rates of cardiovascular events, and they report impaired quality of life.1 Treatment side effects may include diabetes, poor bone health, obesity, infection, reduced fertility, and cancer, and also affect quality of life. Prognostic uncertainty and the potential for disease progression contribute to a substantial psychological burden for patients with GD.
AB - Glomerular diseases (GDs) impose a substantial burden on patients and health systems, and they are a major cause of end-stage kidney disease (ESKD) worldwide.1 The causes and clinical features of GD are diverse, yet as a group they share many symptoms, treatments, and outcomes (Table 1). Patients with primary and secondary GDs have mortality rates 2.7- and 3.9-fold higher than the general population, respectively, higher rates of cardiovascular events, and they report impaired quality of life.1 Treatment side effects may include diabetes, poor bone health, obesity, infection, reduced fertility, and cancer, and also affect quality of life. Prognostic uncertainty and the potential for disease progression contribute to a substantial psychological burden for patients with GD.
KW - chronic kidney disease
KW - clinical trials
KW - core outcome set
KW - glomerulonephritis
KW - outcomes research
KW - patient-centered outcomes
UR - http://www.scopus.com/inward/record.url?scp=85065470867&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2019.01.047
DO - 10.1016/j.kint.2019.01.047
M3 - Article
C2 - 31122702
AN - SCOPUS:85065470867
SN - 0085-2538
VL - 95
SP - 1280
EP - 1283
JO - Kidney International
JF - Kidney International
IS - 6
ER -
